Case Report: Intravenous transplantation of autologous adipose tissue-derived mesenchymal stem cells attenuated atopic dermatitis.

Early human evidence such as case series or small samples is exploring possible benefits.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Mesenchymal stem cells (MSC) transplantation had been shown to have a potential for reducing chronic pain. MSC transplantation suppresses excessive inflammation, and one of the potential mechanisms of action is a gap junction-meditated reduction of vascular permeability. Herein, we present the case of a 32-year-old female patient who underwent autologous adipose tissue-derived MSC transplantation for chronic pain and showed significant improvement in comorbid atopic dermatitis. Moreover, asthma attacks disappeared after MSC transplantation. This case shows that MSC therapy could be effective for treating allergic diseases, at least in responders. These findings encourage future studies to identify responders, surrogate markers, and the detailed therapeutic mechanisms of MSC transplantation for allergic diseases.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.